New leaders appointed at the International Federation of Pharmaceutical Manufacturers & Associations

Published on: 14 June 2012


Masafumi Nogimori and Stefan Oschmann become IFPMA Acting President and Acting Vice President respectively

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) announced changes to its leadership team today. Mr. Masafumi Nogimori of Astellas Pharma Inc. becomes IFPMA Acting President while Dr. Stefan Oschmann of Merck KGaA becomes IFPMA Acting Vice President. These announcements follow the recent resignation of Mr. David Brennan, former CEO of AstraZeneca, as IFPMA President.

Mr. Nogimori is Chairman of Astellas Pharma Inc., a research-based pharmaceutical company located in Tokyo that is dedicated to improving the health of people around the world with innovative and reliable pharmaceuticals. He has served as IFPMA Vice President since 2010.

“Our industry has a long and successful record of partnering with key stakeholders around the world to address global health issues,” said Mr. Nogimori. “IFPMA is an important catalyst in these efforts and I am proud to lead this organization.”

Dr. Oschmann, Merck Executive Board Member and Chief Executive Officer of Merck Serono, brings a wealth of leadership experience to his IFPMA role. He serves along with Mr. John Lechleiter, Chairman, President and CEO of Eli Lilly and Company, who is also IFPMA Vice President.

The IFPMA Assembly will hold the next IFPMA leadership elections in October, 2012.

Geneva, 14 June 2012


IFPMA represents research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry's 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.


Abigail Jones